YU44585B - Process for obtaining substituted androsta-1,4-dien-3,17-diones - Google Patents

Process for obtaining substituted androsta-1,4-dien-3,17-diones

Info

Publication number
YU44585B
YU44585B YU1201/86A YU120186A YU44585B YU 44585 B YU44585 B YU 44585B YU 1201/86 A YU1201/86 A YU 1201/86A YU 120186 A YU120186 A YU 120186A YU 44585 B YU44585 B YU 44585B
Authority
YU
Yugoslavia
Prior art keywords
diones
dien
obtaining substituted
substituted androsta
androsta
Prior art date
Application number
YU1201/86A
Other languages
English (en)
Other versions
YU120186A (en
Inventor
F Buzzetti
N Varmigian
P Lombardy
Salle H Di
Original Assignee
Erba Farmitalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10582036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU44585(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erba Farmitalia filed Critical Erba Farmitalia
Priority to SI8611201A priority Critical patent/SI8611201A8/sl
Publication of YU120186A publication Critical patent/YU120186A/xx
Publication of YU44585B publication Critical patent/YU44585B/xx
Priority to BA970185A priority patent/BA97185B1/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU1201/86A 1985-07-09 1986-07-08 Process for obtaining substituted androsta-1,4-dien-3,17-diones YU44585B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8611201A SI8611201A8 (sl) 1985-07-09 1986-07-08 Postopek za pridobivanje substituiranih androsta -1,4-dien-3,17-dionov
BA970185A BA97185B1 (bs) 1985-07-09 1997-08-13 Postupak za dobijanje supstituisanih androsta-1,4-dien-3,17-diona

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858517360A GB8517360D0 (en) 1985-07-09 1985-07-09 Substituted androsta-1,4-diene-3,17-diones

Publications (2)

Publication Number Publication Date
YU120186A YU120186A (en) 1988-02-29
YU44585B true YU44585B (en) 1990-10-31

Family

ID=10582036

Family Applications (2)

Application Number Title Priority Date Filing Date
YU1201/86A YU44585B (en) 1985-07-09 1986-07-08 Process for obtaining substituted androsta-1,4-dien-3,17-diones
YU1036/87A YU44628B (en) 1985-07-09 1987-06-05 Process for obtaining substituted androsta-1,4-dien,3,17-diones

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU1036/87A YU44628B (en) 1985-07-09 1987-06-05 Process for obtaining substituted androsta-1,4-dien,3,17-diones

Country Status (38)

Country Link
US (2) US4808616A (en:Method)
JP (1) JPS6212797A (en:Method)
KR (1) KR950003614B1 (en:Method)
CN (1) CN86104664B (en:Method)
AT (1) AT395157B (en:Method)
AU (1) AU578840B2 (en:Method)
BE (1) BE905067A (en:Method)
BG (1) BG61370B2 (en:Method)
BR (1) BR1100240A (en:Method)
CA (1) CA1277656C (en:Method)
CH (1) CH668599A5 (en:Method)
CS (2) CS258498B2 (en:Method)
CZ (1) CZ413591A3 (en:Method)
DE (1) DE10199030I1 (en:Method)
DK (1) DK163520C (en:Method)
ES (2) ES8801304A1 (en:Method)
FI (1) FI83424C (en:Method)
FR (1) FR2584725B1 (en:Method)
GB (2) GB8517360D0 (en:Method)
GR (1) GR861780B (en:Method)
HK (1) HK94190A (en:Method)
HU (1) HU194274B (en:Method)
IE (1) IE58949B1 (en:Method)
IL (1) IL79336A (en:Method)
IT (1) IT1196436B (en:Method)
MY (1) MY102294A (en:Method)
NL (2) NL193616C (en:Method)
NO (2) NO165547C (en:Method)
NZ (1) NZ216763A (en:Method)
PH (1) PH21785A (en:Method)
PT (1) PT82944B (en:Method)
SE (1) SE468988B (en:Method)
SG (1) SG80490G (en:Method)
SK (1) SK413591A3 (en:Method)
SU (2) SU1442077A3 (en:Method)
UA (1) UA6046A1 (en:Method)
YU (2) YU44585B (en:Method)
ZA (1) ZA865079B (en:Method)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
GB8622330D0 (en) * 1986-09-17 1986-10-22 Erba Farmitalia 4-substituted 6-alkylidenandrostene-3,17-dione derivatives
DE3715869A1 (de) * 1987-05-07 1988-11-17 Schering Ag Verfahren zur herstellung von 1-methyl-androsta-1,4-dien-3,17-dion und die neuen zwischenprodukte fuer dieses verfahren
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
GB8721383D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia Preparation of methylene derivatives
GB8801697D0 (en) * 1988-01-26 1988-02-24 Erba Farmitalia Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione
ATE154032T1 (de) * 1991-03-28 1997-06-15 Teikoku Hormone Mfg Co Ltd Neue d-homo-17-oxa und d-homo-17-aza- androstanderivate
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
GB9201224D0 (en) * 1992-01-21 1992-03-11 Erba Carlo Spa Difluoromethylenandrostenone derivatives and process for their preparation
CA2145643A1 (en) * 1992-09-30 1994-04-14 Naoyuki Koizumi Novel 7-substituted oxa-or azasteroid compound
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
AU5873300A (en) * 1999-07-07 2001-01-30 Pharmacia & Upjohn Company Process to prepare exemestane
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
AU2001283964A1 (en) * 2000-08-09 2002-02-18 Pharmacia And Upjohn Company Composition for combined use of aromatase inhibitors
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
US20040082557A1 (en) * 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
EP1377298B1 (en) * 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
CZ303611B6 (cs) 2001-02-19 2013-01-09 Novartis Ag Farmaceutické prostredky s obsahem derivátu rapamycinu pro lécení solidních nádoru
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
US20040043938A1 (en) * 2001-11-06 2004-03-04 Dinesh Purandare Combination therapy for estrogen-dependent disorders
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
ATE412408T1 (de) 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
CN1317293C (zh) * 2002-10-24 2007-05-23 南京长澳医药科技有限公司 一种依西美坦的合成工艺
CN1304413C (zh) * 2002-10-24 2007-03-14 上海华拓医药科技发展有限公司 一种抗癌药物依西美坦制备方法
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US7435757B2 (en) * 2004-07-02 2008-10-14 Schering Ag 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US8168621B2 (en) 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
JP5255444B2 (ja) 2005-09-30 2013-08-07 エンディース エルエルシー （ｓ）−６−メチルオキサアルキルエキセメスタン化合物および関連する使用方法
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US20080275259A1 (en) * 2007-05-04 2008-11-06 Scinopharm Taiwan, Ltd Process for preparing aromatase inhibitors
CA2806526C (en) 2007-10-16 2014-12-30 Repros Therapeutics Inc. Trans-clomiphen for type 2 diabetes
EP2070943A1 (en) * 2007-12-14 2009-06-17 Crystal Pharma, S.A. Process for obtaining 6-Alkylidenandrost-1,4-diene-3one
CN101468023B (zh) * 2007-12-26 2011-02-02 上海复星医药（集团）股份有限公司 依西美坦片及其制备工艺
WO2009093262A2 (en) * 2008-01-21 2009-07-30 Cadila Healthcare Limited Process for preparing aromatase inhibitor exemestane
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
WO2010076811A2 (en) * 2008-12-30 2010-07-08 Ind-Swift Laboratories Limited Process for the preparation of exemestane
WO2010127297A1 (en) 2009-05-01 2010-11-04 Parviz Gharagozloo Treating male infertility secondary to sperm oxidative stress
RU2425052C1 (ru) * 2010-03-04 2011-07-27 Татьяна Степановна Савинова Способ получения 6-метиленандрост-4-ен-3,17-диона из андрост-4-ен-3,17-диона, способ получения 6-метиленандроста-1,4-диен-3,17-диона (эксеместана) с использованием полученного 6-метиленандрост-4-ен-3,17-диона
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
WO2011127232A2 (en) 2010-04-08 2011-10-13 Emory University Substituted androst-4-ene diones
WO2011128434A2 (en) 2010-04-16 2011-10-20 Novartis Ag Treatment of endocrine resistant breast cancer
US20120071455A1 (en) 2010-09-14 2012-03-22 Yarger James G 6-substituted demethyl-estradiol derivatives as selective er-beta agonists
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
AU2015216590A1 (en) 2014-02-11 2016-06-30 Novartis Ag Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
CN112409432B (zh) * 2020-11-16 2023-07-07 陕西理工大学 一种依西美坦的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929985A (en:Method) *
US2744120A (en) * 1953-01-14 1956-05-01 Olin Mathieson 1-dehydrotestololactone
US3112305A (en) * 1960-11-07 1963-11-26 British Drug Houses Ltd 6-methylene-3-oxo-delta4-steroids and process for their preparation
GB1042291A (en) * 1961-11-08 1966-09-14 Organon Labor Ltd í¸-6ª‡-amino steroids and the preparation thereof
DK120154B (da) * 1968-02-29 1971-04-19 Schering Ag Fremgangsmåde til fremstilling af N-substituerede 4-amino-3-oxosteroid-4,6-diener af androstan- eller pregnanrækken eller deres ammoniumsalte.
BE759143A (fr) * 1969-11-19 1971-05-19 Upjohn Co Procede de preparation d'un nouveau compose steroide
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3004508C2 (de) * 1980-02-05 1981-12-10 Schering Ag Berlin Und Bergkamen, 1000 Berlin Verfahren zur Herstellung von 6-Methylensteroiden
DE3322285A1 (de) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones

Also Published As

Publication number Publication date
DK324386D0 (da) 1986-07-08
UA6046A1 (uk) 1994-12-29
NL193616B (nl) 1999-12-01
CA1277656C (en) 1990-12-11
NZ216763A (en) 1988-05-30
NO165547B (no) 1990-11-19
DE10199030I1 (de) 2001-10-04
MY102294A (en) 1992-05-15
ES556550A0 (es) 1987-12-16
BE905067A (fr) 1987-01-08
SK413591A3 (en) 1995-07-11
ATA181986A (de) 1992-02-15
NO165547C (no) 1991-02-27
SE8603046L (sv) 1987-01-10
DK163520C (da) 1992-07-27
NO862753L (no) 1987-01-12
PT82944B (pt) 1989-01-30
NO2000009I1 (no) 2000-10-05
AU5979986A (en) 1987-01-15
NL300017I2 (nl) 2001-01-02
AU578840B2 (en) 1988-11-03
CH668599A5 (de) 1989-01-13
CS257794B2 (en) 1988-06-15
SE8603046D0 (sv) 1986-07-08
FR2584725A1 (fr) 1987-01-16
ES8802429A1 (es) 1988-06-01
IE861821L (en) 1987-01-09
GB2177700A (en) 1987-01-28
IL79336A0 (en) 1986-10-31
PH21785A (en) 1988-02-24
BG61370B2 (bg) 1997-06-30
PT82944A (en) 1986-08-01
ES8801304A1 (es) 1987-12-16
CS258498B2 (en) 1988-08-16
SU1501923A3 (ru) 1989-08-15
GR861780B (en) 1986-11-11
JPH0443919B2 (en:Method) 1992-07-20
HU194274B (en) 1988-01-28
DK163520B (da) 1992-03-09
HK94190A (en) 1990-11-23
FI862871A7 (fi) 1987-01-10
CS521486A2 (en) 1987-09-17
HUT42780A (en) 1987-08-28
GB8517360D0 (en) 1985-08-14
KR870001140A (ko) 1987-03-11
IL79336A (en) 1991-06-10
NL300017I1 (nl) 2000-11-01
FI83424C (fi) 1991-07-10
US4904650A (en) 1990-02-27
SE468988B (sv) 1993-04-26
GB8616585D0 (en) 1986-08-13
DK324386A (da) 1987-01-10
IE58949B1 (en) 1993-12-01
JPS6212797A (ja) 1987-01-21
CZ413591A3 (en) 1994-03-16
ZA865079B (en) 1987-03-25
KR950003614B1 (ko) 1995-04-17
BR1100240A (pt) 1999-12-28
CN86104664A (zh) 1987-02-18
IT8621004A0 (it) 1986-07-02
FI83424B (fi) 1991-03-28
YU44628B (en) 1990-10-31
NL8601785A (nl) 1987-02-02
AT395157B (de) 1992-10-12
CN86104664B (zh) 1988-06-29
IT1196436B (it) 1988-11-16
FI862871A0 (fi) 1986-07-07
NL193616C (nl) 2000-04-04
SU1442077A3 (ru) 1988-11-30
FR2584725B1 (fr) 1988-05-13
NO862753D0 (no) 1986-07-08
ES557466A0 (es) 1988-06-01
GB2177700B (en) 1988-12-07
YU103687A (en) 1988-08-31
SG80490G (en) 1990-11-23
US4808616A (en) 1989-02-28
YU120186A (en) 1988-02-29

Similar Documents

Publication Publication Date Title
YU44585B (en) Process for obtaining substituted androsta-1,4-dien-3,17-diones
YU47883A (en) Process for obtaining new 3-keto-delta-4,9,19-nor steroid derivatives
AU8946082A (en) 9lamda-chloro-11beba-hydroxy-16beta-methyl-17lamda,21- dipropionyl-oxypregna-1,4-diene-3,20-dione
PT85121A (en) Process for the preparation of new androst-4-ene-3,17-diones
HUT42136A (en) Process for preparing 4-androsten-3,17-dione 1,4-androstadien-3,17-dione
HUT46077A (en) Process for the microbiological production of 9alpha-hydroxy-4-androsten-3,17-dione
EP0201042A3 (en) 3alpha,5-cyclo-22,23-dihydroxy-5alpha,steroid compounds
GB2155018B (en) 2x-cyano-4d,5x-epoxy-androstane -3,17-dione
GB2152935B (en) (16,17-a) cyclopentano pregnene derivatives
PT85122A (en) Process for the preparation of methylene derivatives of androst-4-ene-3,17-diones
CS240886A2 (en) Method of 1-methyl-1, 4-androstadiene-3, 17-dione production
BA97185B1 (bs) Postupak za dobijanje supstituisanih androsta-1,4-dien-3,17-diona
PL139544B2 (en) Method of obtaining 2-methylene-4,6-androstadiene-3,17-dione
IE871593L (en) Androst-4-ene-3,20-dione derivatives
IE871594L (en) Androst-4-ene-3,20-dione derivatives
IE871874L (en) Androstadiene-3,17-diones
AR243199A1 (es) Procedimiento para elaborar compuestos de 9alfa,21-dihalogeno-llbeta- hidroxi-17alfa-alcanoiloxi-6alfa-fluor-16beta-metil- pregna-1,4-dien-3,20- diona
PL263783A1 (en) Method of obtaining 6-alpha-fluoro-16-alpha,17-alpha-isopropylidenedioxy-11-betha,21-dihydroxy-4-pregnene-3,20-dione
VN22A6 (en) Method for preparing diosgenin
BG39192A1 (en) Method for preparing (4- amino- 3- pyridinyl) phenylketone
HU206728B (en) Process for producing androsta-3,5-diene derivatives
GB8431218D0 (en) Pregnane derivatives
EP0167820A3 (en) Process for the preparation of optionally substituted benz(c,d)-indol-2-ones (naphtholactames)